Akari Therapeutics (AKTX) Getting Somewhat Positive Press Coverage, Analysis Shows
Headlines about Akari Therapeutics (NASDAQ:AKTX) have been trending somewhat positive on Friday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akari Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.5419003997958 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Akari Therapeutics (NASDAQ AKTX) traded down $0.13 during midday trading on Friday, reaching $4.00. 97,751 shares of the company traded hands, compared to its average volume of 383,396. Akari Therapeutics has a 12 month low of $3.18 and a 12 month high of $22.20.
Several brokerages recently issued reports on AKTX. Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a research report on Sunday, September 17th. William Blair upgraded shares of Akari Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, September 22nd. Zacks Investment Research lowered shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Canaccord Genuity restated a “buy” rating and set a $15.00 target price on shares of Akari Therapeutics in a research report on Friday, September 22nd. Finally, ValuEngine upgraded shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $7.50.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.